Investing in Physician AI to Scale Differentiation; Teens% Guidance

Research evidence excerpt

Investing in Physician AI to Scale Differentiation; Teens% Guidance

China (PRC) | Healthcare Information Tech.

Alibaba Health EquityMayResearch19, 2026

TARGET | ESTIMATE CHANGEInvesting in Physician AI to Scale

RATING BUYDifferentiation; Teens% Guidance

PRICE HK$4.10^

Ali Health's Hydrion APP positions it as an early to-doctor AI leader,

HK$5.30 (HK$6.00) |

with execution amid intense competition key to scaling monetization and PRICE TARGET | % TO PT +29%

achieving breakeven by 2029. Mgmt guides 10-15% revenue growth yoy in 52W HIGH-LOW HK$7.91 - HK$4.05

Mar-FY27 with better payout policy. We view ALH largely immune to recent FLOAT (%) | ADV MM (USD) 36.4% | 50.42

news on tighter GLP-1 dispensing in Jiangxi/Shanghai, backed by licensed MARKET CAP HK$66.4B | $8.5B

internet-hospital workflows. With this note, primary coverage transfers to TICKER 241 HK

Hongda Zhong. ^Prior trading day's closing price unless otherwise

noted.

Doubling down on physician-facing AI capabilities: Ali Health (ALH) is emerging as one of

the first movers in to-doctor AI, with the launch of the Hydrion (氢离子) APP, an evidence- FY (Mar) CHANGE TO JEFe JEF vs CONS

based clinical decision support AI tool partnering with British Medical Journal (BMJ). Initial 2027 2028 2027 2028

product testing suggests strong usability with low hallucination and robust clinical reasoning, REV -7% NA NA NA

positioning it competitively against China peers. The strategy mirrors OpenEvidence in the EPS -38% NA NA NA

US, which has scaled rapidly to meaningful ARR with significant pharma advertising demand

(reported ads backlog ~$1bn, valuation ~$12bn). Hydrion offers physicians AI access to 2027 (RMB) 1Half 2Half FY

structured research and clinical knowledge, with pharma/device marketing as the primary EPS -- -- 0.13